Literature DB >> 30368607

Feasibility of lung transplantation from donors mechanically ventilated for prolonged periods.

Seiichiro Sugimoto1, Takeshi Kurosaki2, Shinji Otani2, Shin Tanaka3, Yukiko Hikasa4, Masaomi Yamane3, Shinichi Toyooka3, Motomu Kobayashi4, Takahiro Oto2.   

Abstract

PURPOSE: When patients are mechanically ventilated for more than 5 days, they are usually declined as donors for lung transplantation (LTx); thus, the long-term outcomes of LTx from such donors remain unclear. We investigated the feasibility of LTx from donors that had been mechanically ventilated for prolonged periods.
METHODS: The subjects of this retrospective comparative investigation were 31 recipients of LTx from donors who had been mechanically ventilated for < 5 days (short-term group) and 50 recipients of LTx from donors who had been mechanically ventilated for ≥ 5 days (long-term group).
RESULTS: The median duration of donor mechanical ventilation was 3 days in the short-term group and 8.5 days in the long-term group. However, other than the difference in the duration of donor ventilation, there were no significant differences in the clinical characteristics of the donors or recipients between the groups. The overall survival rate after LTx was comparable between the long-term group and short-term group (5-year survival rate, 66.6% vs. 75.2%).
CONCLUSION: The potential inclusion of donors who have been on mechanical ventilation for more than 5 days could be a feasible strategy to alleviate donor organ shortage.

Entities:  

Keywords:  Brain-dead donor; Extended-criteria donor; Lung transplantation; Marginal donor; Mechanical ventilation

Mesh:

Year:  2018        PMID: 30368607     DOI: 10.1007/s00595-018-1730-z

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  17 in total

Review 1.  Pulmonary transplantation: the role of brain death in donor lung injury.

Authors:  Vassilios S Avlonitis; Andrew J Fisher; John A Kirby; John H Dark
Journal:  Transplantation       Date:  2003-06-27       Impact factor: 4.939

2.  Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation.

Authors:  Jason D Christie; Martin Carby; Remzi Bag; Paul Corris; Marshall Hertz; David Weill
Journal:  J Heart Lung Transplant       Date:  2005-06-04       Impact factor: 10.247

3.  Feasibility and utility of a lung donor score: correlation with early post-transplant outcomes.

Authors:  Takahiro Oto; Bronwyn J Levvey; Helen Whitford; Anne P Griffiths; Tom Kotsimbos; Trevor J Williams; Gregory I Snell
Journal:  Ann Thorac Surg       Date:  2007-01       Impact factor: 4.330

4.  Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes.

Authors:  Luis F Angel; Deborah J Levine; Marcos I Restrepo; Scott Johnson; Edward Sako; Andrea Carpenter; John Calhoon; John E Cornell; Sandra G Adams; Gary B Chisholm; Joe Nespral; Ann Roberson; Stephanie M Levine
Journal:  Am J Respir Crit Care Med       Date:  2006-06-23       Impact factor: 21.405

5.  Donor-to-host transmission of bacterial and fungal infections in lung transplantation.

Authors:  I Ruiz; J Gavaldà; V Monforte; O Len; A Román; C Bravo; A Ferrer; L Tenorio; F Román; J Maestre; I Molina; F Morell; A Pahissa
Journal:  Am J Transplant       Date:  2006-01       Impact factor: 8.086

6.  Extended criteria donor lungs and clinical outcome: results of an alternative allocation algorithm.

Authors:  Wiebke Sommer; Christian Kühn; Igor Tudorache; Murat Avsar; Jens Gottlieb; Dietmar Boethig; Axel Haverich; Gregor Warnecke
Journal:  J Heart Lung Transplant       Date:  2013-08-13       Impact factor: 10.247

7.  Japanese strategies to maximize heart and lung availabilities: experience from 100 consecutive brain-dead donors.

Authors:  N Fukushima; M Ono; S Saito; Y Saiki; S Kubota; Y Tanoue; M Minami; S Konaka; J Ashikari
Journal:  Transplant Proc       Date:  2013-10       Impact factor: 1.066

8.  Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: a randomized controlled trial.

Authors:  Luciana Mascia; Daniela Pasero; Arthur S Slutsky; M Jose Arguis; Maurizio Berardino; Salvatore Grasso; Marina Munari; Silvia Boifava; Giuseppe Cornara; Francesco Della Corte; Nicoletta Vivaldi; Paolo Malacarne; Paolo Del Gaudio; Sergio Livigni; Elisabeth Zavala; Claudia Filippini; Erica L Martin; Pier Paolo Donadio; Ilaria Mastromauro; V Marco Ranieri
Journal:  JAMA       Date:  2010-12-15       Impact factor: 56.272

9.  Early lung retrieval from traumatic brain-dead donors does not compromise outcomes following lung transplantation.

Authors:  Paula Moreno; Antonio Alvarez; Jennifer Illana; Dionisio Espinosa; Carlos Baamonde; Francisco Cerezo; Francisco Javier Algar; Angel Salvatierra
Journal:  Eur J Cardiothorac Surg       Date:  2013-02-20       Impact factor: 4.191

10.  Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome.

Authors:  Phil Botha; Lynda Archer; Rachel L Anderson; Jim Lordan; John H Dark; Paul A Corris; Kate Gould; Andrew J Fisher
Journal:  Transplantation       Date:  2008-03-15       Impact factor: 4.939

View more
  2 in total

1.  Worldwide clinical practices in perioperative antibiotic therapy for lung transplantation.

Authors:  Benjamin Coiffard; Eloi Prud'Homme; Sami Hraiech; Nadim Cassir; Jérôme Le Pavec; Romain Kessler; Federica Meloni; Marc Leone; Pascal Alexandre Thomas; Martine Reynaud-Gaubert; Laurent Papazian
Journal:  BMC Pulm Med       Date:  2020-04-29       Impact factor: 3.317

2.  Meticulous closure of collateral vessels in the perihilar mediastinal pleura to control intraoperative bleeding during lung transplantation for pulmonary hypertension.

Authors:  Haruchika Yamamoto; Seiichiro Sugimoto; Kentaro Imanishi; Kohei Hashimoto; Kentaroh Miyoshi; Shinji Otani; Masaomi Yamane; Shinichi Toyooka
Journal:  J Thorac Dis       Date:  2021-10       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.